Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion type Assertion NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_head.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion wasGeneratedBy ECO_0000203 NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_provenance.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion wasDerivedFrom befree-20140225 NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_provenance.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion SIO_000772 23658459 NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_provenance.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion evidence source_evidence_literature NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_provenance.
- NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_assertion description "[Dovitinib was then evaluated in a phase II trial that included 4 groups of patients with human EGF receptor 2-negative metastatic breast cancer on the basis of FGFR1 amplification and hormone receptor (HR) status.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP562646.RAdGUtXYLF9wmyGZH-MXgVGehvuDiqxRclGmSPsFbOd0M130_provenance.